Sibutramine has been used to produce appetite suppression for the purpose of attaining weight loss in the treatment of patients with obesity.
Sibutramine is a monoamine reuptake inhibitor (MRI) that, in humans, reduces the reuptake of norepinephrine (by ~73%), serotonin (by ~54%), and dopamine (by ~16%), thereby increasing the levels of these substances in synaptic clefts and helping enhance satiety; the serotonergic action, in particular, is thought to influence appetite. Older anorectic agents such as amphetamine and fenfluramine force the release of these neurotransmitters rather than affecting their reuptake.
5.000 mcg Sibutramine.
50 mcg Clenbuterol
500 U.I. Vitamin D3 (Cholecalciferol)
50 U.I. Vitamin E (RRR-alpha-Tocopherol).